Login
Home
Charts
Search
Watchlist
Products

Aster DM Quality Care Ltd

ASTERDM·NSE
755.05-0.74%Fri, 18 Sept '26

Aster DM Quality Care Ltd

ASTERDM
NSE
755.05
-0.74%
|Fri, 18 Sept '26
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
65,816Cr
Close
Close Price
755.05
Industry
Industry
Hospitals
PE
Price To Earnings
122.18
PS
Price To Sales
13.50
Revenue
Revenue
4,876Cr
Rev Gr TTM
Revenue Growth TTM
15.70%
PAT Gr TTM
PAT Growth TTM
3.89%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
9299559741,0021,0861,0501,0001,0781,1971,1861,1821,311
Growth YoY
Revenue Growth YoY%
-67.0-70.120.619.116.910.02.87.610.212.918.221.6
Expenses
ExpensesCr
7848038148388678618088719479759501,046
Operating Profit
Operating ProfitCr
145152159164220189192207250211233264
OPM
OPM%
15.615.916.416.320.218.019.219.220.917.819.720.2
Other Income
Other IncomeCr
17146336-52314-928-86
Interest Expense
Interest ExpenseCr
302530293131323131313031
Depreciation
DepreciationCr
545758606262646366686769
PBT
PBTCr
6177721201591029113616710316378
Tax
TaxCr
8113139533754346441049
PAT
PATCr
-15209-25,1521066486941215915429
Growth YoY
PAT Growth YoY%
-128.331.6-101.225,855.7789.4-69.24,060.2-98.214.7-8.979.5-68.7
NPM
NPM%
-1.621.9-0.2514.39.76.18.68.710.15.013.02.2
EPS
EPS
-0.63.6-0.5103.31.91.11.61.72.11.02.70.3
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
9299559741,0021,0861,0501,0001,0781,1971,1861,1821,311
Growth YoY
Revenue Growth YoY%
-67.0-70.120.619.116.910.02.87.610.212.918.221.6
Expenses
ExpensesCr
7848038148388678618088719479759501,046
Operating Profit
Operating ProfitCr
145152159164220189192207250211233264
OPM
OPM%
15.615.916.416.320.218.019.219.220.917.819.720.2
Other Income
Other IncomeCr
17146336-52314-928-86
Interest Expense
Interest ExpenseCr
302530293131323131313031
Depreciation
DepreciationCr
545758606262646366686769
PBT
PBTCr
6177721201591029113616710316378
Tax
TaxCr
8113139533754346441049
PAT
PATCr
-15209-25,1521066486941215915429
Growth YoY
PAT Growth YoY%
-128.331.6-101.225,855.7789.4-69.24,060.2-98.214.7-8.979.5-68.7
NPM
NPM%
-1.621.9-0.2514.39.76.18.68.710.15.013.02.2
EPS
EPS
-0.63.6-0.5103.31.91.11.61.72.11.02.70.3

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
5,2505,9316,7217,9638,6528,60810,2532,9943,6994,1384,6434,876
Growth
Revenue Growth%
35.513.013.318.58.7-0.519.1-70.823.511.912.215.7
Expenses
ExpensesCr
4,8045,5996,1087,1007,3947,5468,7702,5453,1213,3743,7423,918
Operating Profit
Operating ProfitCr
4463326138631,2581,0631,483449578765901958
OPM
OPM%
8.55.69.110.814.512.314.515.015.618.519.419.6
Other Income
Other IncomeCr
244521773318535126147956-53
Interest Expense
Interest ExpenseCr
18935418517936029425787110124123123
Depreciation
DepreciationCr
243322298306586618641192220249264270
PBT
PBTCr
38108308410330205637195261471570511
Tax
TaxCr
291126431527363657134143149
PAT
PATCr
898282367315178601160205337427363
Growth
PAT Growth%
-97.01,088.0188.830.4-14.3-43.5238.0-73.528.364.526.93.9
NPM
NPM%
0.21.64.24.63.62.15.95.35.58.19.27.4
EPS
EPS
2.25.86.65.53.010.68.52.6108.07.56.2
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
5,2505,9316,7217,9638,6528,60810,2532,9943,6994,1384,6434,876
Growth
Revenue Growth%
35.513.013.318.58.7-0.519.1-70.823.511.912.215.7
Expenses
ExpensesCr
4,8045,5996,1087,1007,3947,5468,7702,5453,1213,3743,7423,918
Operating Profit
Operating ProfitCr
4463326138631,2581,0631,483449578765901958
OPM
OPM%
8.55.69.110.814.512.314.515.015.618.519.419.6
Other Income
Other IncomeCr
244521773318535126147956-53
Interest Expense
Interest ExpenseCr
18935418517936029425787110124123123
Depreciation
DepreciationCr
243322298306586618641192220249264270
PBT
PBTCr
38108308410330205637195261471570511
Tax
TaxCr
291126431527363657134143149
PAT
PATCr
898282367315178601160205337427363
Growth
PAT Growth%
-97.01,088.0188.830.4-14.3-43.5238.0-73.528.364.526.93.9
NPM
NPM%
0.21.64.24.63.62.15.95.35.58.19.27.4
EPS
EPS
2.25.86.65.53.010.68.52.6108.07.56.2

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
403505505497497500500500500518
Reserves
ReservesCr
1,0341,9522,3342,4012,5013,0803,5743,6862,5543,683
Current Liabilities
Current LiabilitiesCr
2,2012,2242,6683,7223,1963,5594,65511,288879979
Non Current Liabilities
Non Current LiabilitiesCr
2,3552,0712,5894,9974,6144,5055,3651,6732,0762,299
Total Liabilities
Total LiabilitiesCr
6,8077,4848,93612,43811,64312,54614,88117,9916,6068,112
Current Assets
Current AssetsCr
2,4722,8693,6174,0963,6294,0964,92214,1651,9011,948
Non Current Assets
Non Current AssetsCr
4,3354,6155,3208,3428,0148,4509,9603,8264,7056,164
Total Assets
Total AssetsCr
6,8077,4848,93612,43811,64312,54614,88117,9916,6068,112
Financial YearMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
403505505497497500500500500518
Reserves
ReservesCr
1,0341,9522,3342,4012,5013,0803,5743,6862,5543,683
Current Liabilities
Current LiabilitiesCr
2,2012,2242,6683,7223,1963,5594,65511,288879979
Non Current Liabilities
Non Current LiabilitiesCr
2,3552,0712,5894,9974,6144,5055,3651,6732,0762,299
Total Liabilities
Total LiabilitiesCr
6,8077,4848,93612,43811,64312,54614,88117,9916,6068,112
Current Assets
Current AssetsCr
2,4722,8693,6174,0963,6294,0964,92214,1651,9011,948
Non Current Assets
Non Current AssetsCr
4,3354,6155,3208,3428,0148,4509,9603,8264,7056,164
Total Assets
Total AssetsCr
6,8077,4848,93612,43811,64312,54614,88117,9916,6068,112

Cash Flow

Consolidated
Standalone
Financial YearMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
3615376011,2231,5691,3141,834158425656
Investing Cash Flow
Investing Cash FlowCr
-1,153-523-709-667-330-570-972-8856,015-288
Financing Cash Flow
Financing Cash FlowCr
65446134-675-1,116-686-8171,053-6,358-304
Net Cash Flow
Net Cash FlowCr
-1386126-11912358453268263
Free Cash Flow
Free Cash FlowCr
-55825747221,2028351,126-59281188
CFO To PAT
CFO To PAT%
369.9190.8163.6388.8882.4218.61,149.277.1126.2153.6
CFO To EBITDA
CFO To EBITDA%
108.687.769.697.3147.688.6408.427.355.672.8
Financial YearMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
3615376011,2231,5691,3141,834158425656
Investing Cash Flow
Investing Cash FlowCr
-1,153-523-709-667-330-570-972-8856,015-288
Financing Cash Flow
Financing Cash FlowCr
65446134-675-1,116-686-8171,053-6,358-304
Net Cash Flow
Net Cash FlowCr
-1386126-11912358453268263
Free Cash Flow
Free Cash FlowCr
-55825747221,2028351,126-59281188
CFO To PAT
CFO To PAT%
369.9190.8163.6388.8882.4218.61,149.277.1126.2153.6
CFO To EBITDA
CFO To EBITDA%
108.687.769.697.3147.688.6408.427.355.672.8

Ratios

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
8,4477,8084,7686,8589,83312,06320,43824,21634,79465,816
Price To Earnings
Price To Earnings
31.423.417.146.218.728.4158.04.589.7122.2
Price To Sales
Price To Sales
1.31.00.60.81.04.05.55.87.513.5
Price To Book
Price To Book
3.42.81.62.32.83.35.48.99.015.7
EV To EBITDA
EV To EBITDA
16.911.77.710.79.738.637.632.539.670.1
Profitability Ratios
Profitability Ratios
GPM
GPM%
56.257.157.657.754.756.240.943.045.346.546.5
OPM
OPM%
8.55.69.110.814.512.314.515.015.618.519.419.6
NPM
NPM%
0.21.64.24.63.62.15.95.35.58.19.27.4
ROCE
ROCE%
11.110.510.88.66.410.52.96.711.710.810.8
ROE
ROE%
6.811.512.910.95.916.83.94.911.010.210.2
ROA
ROA%
1.43.84.12.51.54.81.11.15.15.35.3
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
8,4477,8084,7686,8589,83312,06320,43824,21634,79465,816
Price To Earnings
Price To Earnings
31.423.417.146.218.728.4158.04.589.7122.2
Price To Sales
Price To Sales
1.31.00.60.81.04.05.55.87.513.5
Price To Book
Price To Book
3.42.81.62.32.83.35.48.99.015.7
EV To EBITDA
EV To EBITDA
16.911.77.710.79.738.637.632.539.670.1
Profitability Ratios
Profitability Ratios
GPM
GPM%
56.257.157.657.754.756.240.943.045.346.546.5
OPM
OPM%
8.55.69.110.814.512.314.515.015.618.519.419.6
NPM
NPM%
0.21.64.24.63.62.15.95.35.58.19.27.4
ROCE
ROCE%
11.110.510.88.66.410.52.96.711.710.810.8
ROE
ROE%
6.811.512.910.95.916.83.94.911.010.210.2
ROA
ROA%
1.43.84.12.51.54.81.11.15.15.35.3
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Aster DM Healthcare began as a single-doctor clinic in Dubai in 1987 and has since transformed into one of India’s top three private hospital chains by bed capacity, now operating as a pure-play domestic healthcare provider after separating its Gulf business and merging with Blackstone-backed Quality Care India. The recurring approach is to build or acquire hospitals in underserved markets, fill them with high-end clinical talent and technology, and then deepen their profitability by shifting the patient mix toward complex, higher-value procedures - a playbook it has run from its first Indian hospital in Kozhikode to its latest merger creating a pan-India platform. # Business segments Three engines at different stages - a mature hospital network generating the bulk of cash, a young diagnostics chain approaching breakeven, and a retail pharmacy network being restructured - all stitched together by a digital health backbone. ## 1. Hospitals and clinics: where the group’s cash and reputation are built **A network of 39 hospitals with over 10,600 beds treats patients across every tier of care, earning revenue on a fee-for-service basis while steadily shifting toward complex, high-value procedures that command better pricing.** - **Paid per patient, not per bed** - revenue comes from in-patient stays and out-patient visits, driven by how many beds are filled (61% occupancy at Aster standalone in FY26), how long patients stay (3.1 days on average), and what the hospital earns per occupied bed (INR 51,800 ARPOB). The combined entity post-merger tracks ARPP IP - average revenue per in-patient - which stood at INR 127,074 in FY26, reflecting the higher-acuity case mix QCIL brings. - **Complex procedures lift the ceiling** - no single specialty accounts for more than 15% of hospital revenue, but the top six - cardiac sciences, neurology, oncology, liver care, nephrology, and orthopaedics - together contributed 57% in FY25. The company deliberately steers toward these under its CONGO-T framework (Cardiology, Oncology, Neurology, Gastroenterology, Transplants) because they carry higher margins and are harder for smaller rivals to replicate. - **Three clusters, three different jobs** - the Kerala cluster, anchored by Aster Medcity in Kochi and MIMS in Kozhikode, is the mature profit engine contributing 53% of hospital revenue in FY25. Karnataka and Maharashtra, led by Aster CMI and Aster Whitefield in Bengaluru, is the growth engine at 35% of revenue, while Andhra Pradesh and Telangana is the emerging frontier built around the acquired Ramesh Hospitals group. - **Maturity determines margin** - hospitals older than seven years delivered a 25.4% EBITDA margin and 36.5% return on capital employed in FY26, while those under three years ran at just 10.5% with zero ROCE, because new hospitals need time to build doctor referrals and patient trust before they can fill beds with higher-paying procedures. This is why the company’s 4,445-bed expansion pipeline - including greenfield projects in Kasargod, Trivandrum, Sarjapur Road Bengaluru, and Hyderabad - is a bet that today’s investment will become tomorrow’s mature cash generator. - **An asset-light side door into smaller cities** - four hospitals with 554 beds run on an operations-and-maintenance model where Aster manages the facility for a fee rather than owning it, earning both fixed and variable payments at a lower ARPOB of roughly INR 20,000 because these units treat more government-scheme patients. It is a low-risk way to test demand in tier-2 and tier-3 towns before committing capital. ## 2. Aster Labs: the diagnostics network feeding the hospital funnel **A hub-and-spoke pathology chain of over 300 collection centres and labs runs more than 2,500 types of tests, serving both the company’s own hospitals and external patients while acting as a referral feeder into the hospital system.** - **Built on the hospital brand** - launched in 2019 under the promise “The True Test,” the labs business inherited the trust of a 35-year healthcare name, which matters when patients are choosing where to get blood work or a biopsy read. It now operates one reference lab, 13 satellite labs, nine hospital lab managements, and 248 patient experience centres across six states. - **Broke even by plugging into existing infrastructure** - the business reached EBITDA breakeven in Q4 FY24 by consolidating hospital lab work under Aster Labs and sharing resources across clusters, so it did not have to build a customer base from scratch. Since inception it has served over 3.24 million patients and performed 12.3 million tests as of March 2023. - **A small slice today, a referral engine tomorrow** - at 3% of total revenue in FY26, the labs business is modest, but every test result that flags a serious condition creates a direct path into the company’s hospital network for treatment. ## 3. Aster Pharmacy (India retail): a branded storefront being refocused **A chain of 203 retail pharmacies sells medicines and wellness products under the Aster brand, operated by a separate licensee, while the company has exited a loss-making wholesale unit to stop the drag on growth.** - **Brand licence, not owned operations** - the pharmacies are run by Alfaone Retail Pharmacies Private Limited under a brand licence from Aster, meaning the company earns a fee without carrying the full operating risk of retail. The network spans Karnataka, Kerala, Telangana, and Andhra Pradesh. - **Cutting the loss-maker** - the company deliberately exited a loss-making wholesale pharmacy unit, which suppressed reported revenue growth but removed a drain on profitability, signalling that this segment is being managed for contribution, not scale at any cost. # Digital health and technology platforms **A shared digital layer - spanning a patient app, an AI-driven reactivation engine, and a 24/7 teleradiology hub - sits across all three businesses to pull patients back into the system and make the network stickier.** - **The app that speaks the local language** - the Aster Health App, launched in November 2024 across 10 hospitals, had over 100,000 downloads and over 20,000 active monthly users by FY25, with a Malayalam version making it Kerala’s first regional-language healthcare super app. It handles appointment booking, lab reports, and radiology reports in one place. - **Winning back dormant patients with algorithms** - the AsterCare programme analyses health records to identify patients who have stopped coming and re-engages them, achieving an 8% reactivation rate in pilots and recovering over 6,500 patients, which is essentially free revenue from an existing database. - **Reading scans while India sleeps** - Aster Medical Imaging runs a centralized teleradiology hub that interprets MRI, CT, and X-ray scans remotely for both Aster hospitals and external clients, using time-zone differences to offer overnight reporting for international customers and “pre-read” services. It turns an internal capability into a third-party revenue stream. # Group structure and partners **The listed entity, Aster DM Quality Care Limited, is jointly controlled by the founding Moopen family and Blackstone following a merger that created a top-three pan-India hospital platform, with the legacy Gulf business now entirely separated.** - **A clean split from the Gulf** - on April 3, 2024, a consortium led by sovereign-backed Fajr Capital acquired 65% of the GCC business, while the Moopen family kept 35% and operational rights, leaving the listed India entity as a pure domestic play with the family holding 41.88%. The two sides are bound by a non-compete agreement preventing operations in each other’s core regions. - **The Blackstone merger created the scale** - effective July 1, 2026, Aster merged with Quality Care India Limited, a Blackstone-backed hospital group, in a share-swap deal that gave Blackstone 30.7% of the combined entity and Aster promoters 24.0%, with equal board representation and joint control. The merged company operates 39 hospitals across 28 cities under four brands - Aster DM, CARE Hospitals, KIMSHEALTH, and Evercare - and has a presence in Bangladesh as well. - **Subsidiaries do the heavy lifting** - Malabar Institute of Medical Sciences (MIMS), the Kerala hospital operator, is a material subsidiary that Aster is consolidating to 100% ownership. New greenfield projects in Bengaluru - a 430-bed hospital on Sarjapur Road and a super-specialty facility in Yeshwantpur - are housed in separate wholly owned subsidiaries, with external investors brought in via compulsory convertible preference shares while Aster keeps at least 75%. - **A captive solar plant to lock in power costs** - in April 2026, Aster and MIMS acquired a 26% stake in a solar power developer that will build an 18 MWp plant in Kerala, with the hospitals buying 100% of the output, meeting statutory captive-user rules under the Electricity Act while insulating against grid-price volatility.

Documents — Aster DM Quality Care Ltd

  • Q1 FY2027 Earnings Call Transcript (Jun 2026, PDF): https://www.stockscans.in/document/vde4v81grcvw3dynuplx9j3v.pdf
  • Q4 FY2026 Earnings Call Transcript (Mar 2026, PDF): https://www.stockscans.in/document/rqug6zdlhm9w10t8p8irwpnl.pdf
  • Q3 FY2026 Earnings Call Transcript (Dec 2025, PDF): https://www.stockscans.in/document/x7nmef9impy7iujkn7sk6mk4.pdf
  • Q2 FY2026 Earnings Call Transcript (Sep 2025, PDF): https://www.stockscans.in/document/8u85o64k3spu9zpz661hs8pg.pdf
  • Q4 FY2025 Earnings Call Transcript (Mar 2025, PDF): https://www.stockscans.in/document/3gt47sekfhc7k41doy45q1rm.pdf
  • Q3 FY2025 Earnings Call Transcript (Dec 2024, PDF): https://www.stockscans.in/document/651bhz9thqmnpgwx1yv2hfyt.pdf
  • Q2 FY2025 Earnings Call Transcript (Sep 2024, PDF): https://www.stockscans.in/document/ubb0kmvh1t5rzfnrjlbtpqeb.pdf
  • Q1 FY2025 Earnings Call Transcript (Jun 2024, PDF): https://www.stockscans.in/document/2byu5rl6w20nqxio4elimj37.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/9un2ky089eli9y2xakuj67i1.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/y4n8148dk0tvst3gryt0ach0.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/e8flo642xc4isezvaexb5r99.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/gs7suqx3ejsjtuwzhsf56qvf.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/ih0asfnqiun0axtmyjfa398o.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/32w8v6rvdtgrh7cea151rsaj.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/2yo86d3l9oec1ymthxnhkk50.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/eudr7letg5b5jb0xzi0uvmra.pdf
  • Q1 FY2027 Investor Presentation (Jun 2026, PDF): https://www.stockscans.in/document/njfouakza4z9ggaato9nmbx4.pdf
  • Q4 FY2026 Investor Presentation (Mar 2026, PDF): https://www.stockscans.in/document/74p9587fji07l2biam64n6go.pdf
  • Q3 FY2026 Investor Presentation (Dec 2025, PDF): https://www.stockscans.in/document/4eukhyhaopq8sts3108jdf7y.pdf
  • Q2 FY2026 Investor Presentation (Sep 2025, PDF): https://www.stockscans.in/document/oal7vsq52ns1onxcoullimd8.pdf
  • Q1 FY2026 Investor Presentation (Jun 2025, PDF): https://www.stockscans.in/document/ip03vttmj9m89hqotk5lsx99.pdf
  • Q4 FY2025 Investor Presentation (Mar 2025, PDF): https://www.stockscans.in/document/jwz6t8wdpjvzqa1sn321i655.pdf
  • Q3 FY2025 Investor Presentation (Dec 2024, PDF): https://www.stockscans.in/document/ac4hq1gigvklro7at9fde0q0.pdf
  • Q2 FY2025 Investor Presentation (Sep 2024, PDF): https://www.stockscans.in/document/7umihipjqysp15oil8exgdlq.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/11pdaq318xysbjdb69s0h51i.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/qy2h5it4xncgj7m2jrwwh9zg.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/4x754hchzo1d4v5davsr8u0u.pdf
  • FY2022 Annual Report (PDF): https://www.stockscans.in/document/hxht3eg9e0q1d76v9ob8of81.pdf
  • FY2021 Annual Report (PDF): https://www.stockscans.in/document/w3vu8fgyqhlmmx515kf077zr.pdf
  • FY2020 Annual Report (PDF): https://www.stockscans.in/document/rtfkf260jgq8yhhjv5rhefmh.pdf

Concall Transcript Summaries — Aster DM Quality Care Ltd

  • Q1 FY2027 Concall Transcript Summary (Jun 2026): https://www.stockscans.in/company/NSE%3AASTERDM/transcript-notes/202606/vde4v81grcvw3dynuplx9j3v.pdf
  • Q4 FY2026 Concall Transcript Summary (Mar 2026): https://www.stockscans.in/company/NSE%3AASTERDM/transcript-notes/202603/rqug6zdlhm9w10t8p8irwpnl.pdf
  • Q3 FY2026 Concall Transcript Summary (Dec 2025): https://www.stockscans.in/company/NSE%3AASTERDM/transcript-notes/202512/x7nmef9impy7iujkn7sk6mk4.pdf
  • Q2 FY2026 Concall Transcript Summary (Sep 2025): https://www.stockscans.in/company/NSE%3AASTERDM/transcript-notes/202509/8u85o64k3spu9zpz661hs8pg.pdf
  • Q4 FY2025 Concall Transcript Summary (Mar 2025): https://www.stockscans.in/company/NSE%3AASTERDM/transcript-notes/202503/3gt47sekfhc7k41doy45q1rm.pdf
  • Q3 FY2025 Concall Transcript Summary (Dec 2024): https://www.stockscans.in/company/NSE%3AASTERDM/transcript-notes/202412/651bhz9thqmnpgwx1yv2hfyt.pdf
  • Q2 FY2025 Concall Transcript Summary (Sep 2024): https://www.stockscans.in/company/NSE%3AASTERDM/transcript-notes/202409/ubb0kmvh1t5rzfnrjlbtpqeb.pdf
  • Q1 FY2025 Concall Transcript Summary (Jun 2024): https://www.stockscans.in/company/NSE%3AASTERDM/transcript-notes/202406/2byu5rl6w20nqxio4elimj37.pdf